GE Healthcare unveils new CT System, aiming to Improve CVD Diagnosis

GE HealthCare introduced its new computed tomography (CT) system, intended to support healthcare professionals in diagnosing difficult coronary artery disease (CAD). The Revolution Vibe system was launched formally at the American College of Cardiology (ACC) 2025 meeting, held in Chicago between March 29 and March 31. The Revolution Vibe system, through Cardiac CT Angiography (CCTA), uses contrast dyes to create images of the blood vessels and aid in the diagnosis of severe cardiovascular diseases (CVDs) like atrial fibrillation and severely calcified coronary arteries. 

Cardiovascular diseases are responsible for the highest number of deaths globally, and according to research, coronary and stroke deaths in the US may rise by about 18%, adding about 67,000 extra coronary deaths per year by 2030. Between 2025 and 2050, there is expected to be a whopping 90% increase in CVD prevalence.

Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare, stated, “Expanding access to CCTA is essential for addressing the growing prevalence of CVD and ensuring timely, accurate diagnoses for a broader patient population. The launch of Revolution Vibe highlights our dedication to this goal.”

The Revolution Vibe system includes Unlimited One-Beat Cardiac technology, which GE HealthCare provides to obtain high-quality images during patient exams. It's True Fidelity DL images for cardiac exams and Snapshot Freeze 2 technology improve image quality, and the ECG-less cardiac function enables CT scans to be taken without an attached ECG monitor. To simplify cardiac scans, Vibe's AI-powered Effortless Cardiac Workflow can pick scan protocols and position patients prior to scanning, which can lower procedure times and ease processes for junior technologists.

Dr. Christopher Ahlers, a radiologist at Radiomed, a German radiology practice and an early user of Vibe, reported that the system has doubled their CCTA capacity, shortened scan times, and improved image quality. He said, "By implementing Revolution Vibe, we have enhanced operational efficiency, increased diagnostic confidence, and improved patient satisfaction, enabling us to stay at the forefront of cardiac care." Along with the Vibe system, GE HealthCare has launched a new, state-of-the-art ultrasound system that is a "significant advancement" in breast cancer detection, according to market analysis. GE HealthCare also made public at the ACC meeting its plans to introduce Flyrcado, a unit-dose PET myocardial perfusion imaging (MPI) agent for patients with known or suspected CAD. The US Food and Drug Administration approved this injection last year.